Ser176
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser176  -  DEAF1 (human)

Site Information
PLtPGPQsPPtPLAP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449147

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 )
Disease tissue studied:
breast cancer ( 5 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , leukemia ( 10 , 14 , 16 ) , acute lymphocytic leukemia ( 11 ) , acute myelogenous leukemia ( 10 , 14 , 16 ) , lung cancer ( 9 ) , non-small cell lung cancer ( 9 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

4

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

5

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

6

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

7

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

8

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

9

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

10

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

11

Gu TL, et al. (2011) Survey of activated FLT3 signaling in leukemia. PLoS One 6, e19169
21552520   Curated Info

12

Possemato A (2010) CST Curation Set: 8990; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

13

Moritz A (2010) CST Curation Set: 9057; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

14

Gu T (2009) CST Curation Set: 7661; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

15

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

16

Gu T (2007) CST Curation Set: 2608; Year: 2007; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

17

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info